Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07067788 · ClinicalTrials.gov registry record
B.Brilliant Revelation Comparision Study
A clinical trial of Breast Cancer Screening, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07067788: Recruiting study of Breast Cancer Screening, sponsored by University of Pennsylvania.
NCT07067788 is a study of Breast Cancer Screening that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 63,430-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07067788, a study of Breast Cancer Screening, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices
Primary Outcome
• To assess whether the MAMMOMAT B.brilliant, a Novel Wide-Angle Digital Breast Tomosynthesis (NDBT) System, leads to better visualization of calcifications compared to the MAMMOMAT Revelation, a standard wide-angle Digital Breast Tomosynthesis (DBT) System, including the assessment of calcifications on synthetic images for both tomosynthesis scans.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Breast Imaging
Study Locations (1)
Pennsylvania
- Pennsylvania Hospital, Center for Breast Imaging - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2027-01-30 |
What NCT07067788 shows while recruiting
NCT07067788 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 63,430-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Breast Cancer Screening appearing as the primary indexed condition, and to 1 intervention - of which Breast Imaging is the first listed.
NCT07067788 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07067788 about?
NCT07067788 is a clinical study titled "B.Brilliant Revelation Comparision Study". This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices
What is the current status of trial NCT07067788?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-12-15. Estimated completion is 2027-01-30.
What conditions does trial NCT07067788 study?
This clinical trial studies the following conditions: Breast Cancer Screening.
What interventions are being tested in trial NCT07067788?
The interventions under investigation include: Breast Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07067788?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07067788 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Screening
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07067788's enrollment target sits among peer trials
100 7th of 8 higher than 1 of 8 other Breast Cancer Screening trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Screening trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
RECRUITING · Phase 4
-
MADRE (Mammograms Available Due to Research and Education)
RECRUITING · NA
-
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
RECRUITING · NA
-
Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography
COMPLETED
-
Adapting a Mammography Decision Aid to Support Women Living in a Community Contaminated by PFAS
COMPLETED · NA
-
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI